Adds details in paragraphs 3, 4 and 5
April 25 (Reuters) - Eli Lilly LLY.N has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday.
Last month, the regulator had rejected the drug, Kisunla, saying that the treatment's ability to slow cognitive decline was not large enough to outweigh the risk of serious brain swelling in patients.
Lilly had said at the time that it planned to seek a re-examination from the regulator.
Upon receiving the grounds of the request, the agency said it will reconsider its opinion and issue a final recommendation for the drug.
Lilly's drug is already approved in the United States.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Saumyadeb Chakrabarty)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.